| 37th week of 2011 patent applcation highlights part 47 |
| Patent application number | Title | Published |
|---|
| 20110224106 | Production Of Single-Stranded Circular Nucleic Acid - A method is provided for generating single stranded circular nucleic acid from a sample of target nucleic acid. A complex comprising a transposase and a plurality of hairpin polynucleotides is formed with each of the hairpin polynucleotides having a duplex region comprising a transposase recognition sequence. The complex is mixed with the target nucleic acid, thereby fragmenting the target nucleic acid and ligating the hairpin polynucleotides to the target nucleic acid to form hairpin-linked nucleic acid fragments, each having a nucleobase segment gap between each fragment and its corresponding hairpin polynucleotide. The hairpin-linked fragments are contacted with a ligase, thereby ligating the hairpin-linked fragments together to form single-stranded circular nucleic acid comprising a pair of opposing loops and an intervening duplex region comprising a pair of nucleobase segment gaps. The single-single stranded circular nucleic acid is then contacted with a polymerase and nucleotide triphosphates, thereby filling the nucleobase segment gaps. | 2011-09-15 |
| 20110224107 | HYDROLYZED NITRILOTRIACETONITRILE COMPOSITIONS, NITRILOTRIACETONITRILE HYDROLYSIS FORMULATIONS AND METHODS FOR MAKING AND USING SAME - Hydrolyzed nitrilotriacetonitrile compositions are disclosed prepared by a method characterized by a one-shot addition of an amount of nitrilotriacetonitrile to a solution containing an acid catalyst, where the reaction is complete in a time period of less than an hour. The method is also characterized by adjusting the pH of the reaction mixture to a pH of at least 8. The method is also characterized by oxidatively removing free cyanide to a desired low level through the addition of an oxidizing agent the produces environmentally benign by-products to the crude hydrolyzed NTAN to form hydrolyzed NTAN compositions having minimized, negligible, or substantially no free cyanide levels. | 2011-09-15 |
| 20110224108 | WATER-BASED POLYMER DRILLING FLUID AND METHOD OF USE - A water-based drilling fluid comprises a polymer which is a non-ionic polymer or an anionic polymer. The polymer can be a polyaerylamide. The fluid is used for drilling subterranean formations containing heavy crude oil and bitumen-rich oil sands, and may comprise additional fluid components. | 2011-09-15 |
| 20110224109 | Reversible Peptide Surfactants For Oilfield Applications - The invention discloses a foam composition comprising a self-assembled, force-transmitting peptide network prepared by: a) dissolving or dispersing a peptide surfactant in a liquid to form a solution; and b) mixing the solution with a gas (e.g., nitrogen, carbon dioxide) to form a foam. | 2011-09-15 |
| 20110224110 | Particles in Oil for Viscoelastic Surfactant Gelled Fluids - Fluids viscosified with viscoelastic surfactants (VESs) may have their fluid loss properties improved with the presence of at least one mineral oil in combination with at least one particulate fluid loss control agent that may be an alkaline earth metal oxides, alkaline earth metal hydroxides, transition metal oxides, transition metal hydroxides, and mixtures thereof. The mineral oil may initially be dispersed oil droplets in an internal, discontinuous phase of the fluid. In one non-limiting embodiment, the mineral oil is added to the fluid after it has been substantially gelled. The particulate fluid loss control agent may be added in any order relative to the VES and the mineral oil fluid loss control agent. The mineral oil may enhance the ability of a particulate fluid loss control agent to reduce fluid loss. The presence of the mineral oil may also eventually reduce the viscosity of the VES-gelled aqueous fluid. | 2011-09-15 |
| 20110224111 | BIODEGRADABLE ANIONIC ACID CORROSION INHIBITOR COMPRISING SARCOSINES - An acid treatment composition is provided including an alkyl sarcosinate as corrosion inhibitor and an optional corrosion inhibitor intensifier in an acidic solution. Methods for treating wells with these acid treatment compositions are also provided that help control corrosion of the alloy surfaces used in the wells during the acid treatment. | 2011-09-15 |
| 20110224112 | SLIDING PART MADE OF Pb-FREE Cu-Bi BASED SINTERED ALLOY - Sliding parts are made of Pb-free Cu-Bi based sintered material. The side in contact with a shaft is machined to a predetermined roughness. A number of Bi phases are present on the finished surface. Stable performance of Bi is to be exhibited. Machined sintered material covers a portion of the Bi phases. The ratio of the exposed surface area of the Bi phases is 0.5% or more relative to the area of the finished surface. | 2011-09-15 |
| 20110224113 | Method of Making Carbon Nanotube Dispersions for the Enhancement of the Properties of Fluids - A method for the preparation of carbon nanotube modified fluids such, that the dispersion of nanotubes in such fluids, exampled by those which are oil based is enhanced through the combined use of mechanical, sonic and ultrasonic devices. | 2011-09-15 |
| 20110224114 | Morpholine Derivatives as Ashless TBN Sources and Lubricating Oil Compositions Containing Same - Morpholine derivatives useful as ashless TBN sources for lubricating oil compositions that are compatible with fluoroelastomeric engine seal materials, and lubricating oil compositions containing such compounds. | 2011-09-15 |
| 20110224115 | Reducing High-Aqueous Content Sludge in Diesel Engines - Formation of high-aqueous content sludge may be reduced in a sump lubricated diesel engine lubricated with a lubricating oil formulation that contains at least 0.07 or 0.08 weight percent nitrogen derived from one or more nitrogen-containing ashless dispersants, by including in the lubricant a polyalkylene oxide. | 2011-09-15 |
| 20110224116 | METHODS FOR CLEANING AN AUTOMATIC BIOCHEMICAL ANALYZER - A method of cleaning an automatic biochemical analyzer, wherein the cleaning solution includes: at least one anionic surfactant, at least one nonionic surfactant, an alkali metal hydroxide, an alkali metal citrate, and a buffering agent stabilizing the pH value above 13.0. In some embodiments, the cleaning solution provides low residual rate of proteins, low residual rate of lipids, desirable within-batch repeatability in clinical testing, low level of cross-contamination, and low level of reactant deposit after cleaning, without affecting test results of the biochemical analyzer. In some embodiments, the cleaning solution has no corrosive effects on the liquid path and reaction cup of the analyzer. The ingredients of the cleaning solution may also be biodegradable. | 2011-09-15 |
| 20110224117 | INK CLEANING LIQUID - An ink cleaning liquid includes ethylene glycol monobutyl ether acetate and a surfactant. | 2011-09-15 |
| 20110224118 | Scale-reducing additive for automatic dishwashing systems - An automatic dishwashing detergent composition having at least two components. The first component is a polymer containing polymerized residues of at least one C | 2011-09-15 |
| 20110224119 | Scale-reducing additive for automatic dishwashing systems - An automatic dishwashing detergent composition having at least two components. The first component is a polymer containing polymerized residues of at least one C | 2011-09-15 |
| 20110224120 | WASHING, CLEANING, POST-TREATING OR AUXILIARY WASHING AGENT CONTAINING SILVER - The present invention relates to liquid washing, cleaning, post-treating or auxiliary washing agents comprising surfactant, silver and/or a silver compound, along with additional active ingredients typically used in washing, cleaning, post-treating or auxiliary washing agents, whereby the agents are stabilized by the addition of a non-neutralized fatty acid. | 2011-09-15 |
| 20110224121 | NONIONIC SURFACTANT BLENDS USING SEED OILS - Described are nonionic surfactant blends comprising the transesterification product of poly(ethylene glycol), preferably methoxy-poly(ethylene glycol), and a seed oil, such as castor oil, soybean oil, olive oil, palm oil, palm kernel oil, peanut oil, rapeseed oil, corn oil, sesame seed oil, cottonseed oil, canola oil, safflower oil, linseed oil, coconut oil, or sunflower oil, or blends thereof. | 2011-09-15 |
| 20110224122 | Cleaning Composition and Method - A cleaning composition comprises a water-in-oil emulsion. The aqueous phase comprises a source of active oxygen. The oil phase comprises a bleach activator in particulate form. | 2011-09-15 |
| 20110224123 | POLYPEPTIDES HAVING LIPASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME - The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 2011-09-15 |
| 20110224124 | pH Tuneable Amido-Gellant For Use In Consumer Product Compositions - The invention is to pH tuneable amido-gellant that are suitable for use in consumer product compositions. | 2011-09-15 |
| 20110224125 | 3-CHLORO-1,1,1,6,6,6-HEXAFLUORO-2,4-HEXADIENE AND SOLVENT COMPOSITIONS CONTAINING THE SAME - Disclosed are compositions and systems having utility in numerous situations, including in particular solvent cleaning systems, as well as refrigerant lubricants and/or compatibilizing agents, and to methods which utilize such compositions and systems. More particularly, the present invention in preferred aspects is directed to solvents, blowing agents, heat transfer fluids and compatibilizing agents comprising the compound 3-chloro-1,1,1,6,6,6-hexafluoro-2,4-hexadiene. | 2011-09-15 |
| 20110224126 | LIQUID DETERGENT COMPOSITION - The invention provides a liquid detergent composition containing (a) a nonionic surfactant obtained by adding ethylene oxide and an alkylene oxide with from 3 to 5 carbon atoms to a compound represented by R—OH (wherein R represents an alkyl group or an alkenyl group with from 8 to 18 carbon atoms) under a specified condition, (b) an anionic surfactant and (c) a water-miscible organic solvent in specified ratios, respectively. | 2011-09-15 |
| 20110224127 | Perfume Encapsulate, a Laundry Detergent Composition Comprising a Perfume Encapsulate, and a Process for Preparing a Perfume Encapsulate - A process for preparing an encapsulate, the process having the steps of: (i) emulsifying a hydrophobic perfume-polymer complex in water to form an oil in water emulsion; (ii) at least partially dissolving an encapsulating material in water; (iii) removing at least some water from the oil in water emulsion comprising the hydrophobic perfume-polymer complex and the encapsulating material to form an encapsulate. | 2011-09-15 |
| 20110224128 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY - The invention features methods, compositions, and kits useful for the treatment of muscular dystrophy, e.g., Duchenne muscular dystrophy, in a patient. | 2011-09-15 |
| 20110224129 | Lipopeptide Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain lipopeptide compounds comprising a cyclic peptide bearing a lipid side chain (for convenience, collectively referred to herein as “LP compounds”), which, inter alia, are antimicrobial, particularly antibacterial. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to provide an antimicrobial function, particularly an antibacterial function, and in the treatment of diseases and conditions that are mediated by microbes, particularly bacteria, that are ameliorated by the antimicrobial function, particularly an antibacterial function, including bacterial diseases, optionally in combination with another agent, for example, another antibacterial agent. | 2011-09-15 |
| 20110224130 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS - This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds. | 2011-09-15 |
| 20110224131 | ANTIFUNGAL PAINTS AND COATINGS - Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compostions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed. | 2011-09-15 |
| 20110224132 | USE OF THE LONG PENTRAXIN PTX3 FOR THE PREVENTION OR TREATMENT OF VIRAL DISEASES - It is described the use of the long pentraxin PTX3 (PTX3) or one of its functional derivatives, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation. | 2011-09-15 |
| 20110224133 | Highly Potent Peptides To Control Cancer And Neurodegenerative Diseases - This invention provides compositions and method of diminishing or inhibiting autophagy by administering a FLIP protein that binds to Atg3, interfering with the formation of the LC3-Atg4-Atg7-Atg3 conjugation complex necessary for autophagy induction. This invention also provides FLIP peptide fragments that promote or induce autophagy by interfering with the activity of FLIP. | 2011-09-15 |
| 20110224134 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS - The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections. | 2011-09-15 |
| 20110224135 | USE OF CONKUNITZIN-S1 FOR THE MODULATION OF GLUCOSE-INDUCED INSULIN SECRETION - The present invention relates to a (poly)peptide or a peptidomimetic thereof having the biological activity of Conkunitzin-S1, wherein said (poly)peptide is selected from (a) a polypeptide comprising or having the amino acid sequence of SEQ ID NO: 1; (b) a polypeptide having at least 85% sequence identity to SEQ ID NO:1; or (c) a fragment of a) or b); wherein said (poly)peptide or peptidomimetic specifically modulates the activity of a channel having the activity of a Kv1.7 containing channel, for the treatment or prevention of metabolic diseases or conditions, or secondary diseases or conditions related to said metabolic diseases or conditions. The present invention furthermore relates to a method of screening for (poly)peptides derived from Conkunitzin-S1 suitable for specifically modulating the activity of a channel having the activity of a Kv1.7 containing channel, comprising: (a) altering the amino acid sequence of Conkunitzin-S1 represented by SEQ ID NO: 1 by deleting and/or inserting and/or replacing at least one amino acid; and (b) determining the modulatory effect of the (poly)peptide obtained in step (a) (i) on a channel having the activity of a Kv1.7 containing channel and (ii) on channels, preferably potassium channels, not having the activity of a Kv1.7 containing channel, which are optionally expressed on the same cell as the channel having the activity of a Kv1.7 containing channel. | 2011-09-15 |
| 20110224136 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE - The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below. | 2011-09-15 |
| 20110224137 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE - The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown below: formula (I). | 2011-09-15 |
| 20110224138 | METHODS FOR TREATING PAIN INDUCED BY INJURIES AND DISEASES OF AN ARTICULAR JOINT - Described herein are methods for using bone morphogenetic proteins (BMPs), such as OP-1 (also known as BMP-7), to treat pain caused by osteoarthritis. The methods involve administering to a patient suffering from pain caused by osteoarthritis a BMP, for example, intraarticularly by injection directly into the joint afflicted with osteoarthritis. The methods of the invention provide long-term pain relief to sufferers of osteoarthritis and can improve the functionality of the joint to which the BMP is administered. | 2011-09-15 |
| 20110224139 | PROTEASE-RESISTANT MUTANTS OF STROMAL CELL DERIVED FACTOR-1 IN THE REPAIR OF TISSUE DAMAGE - The present invention features mutant stromal cell derived factor-1 (SDF-1) peptides that have been mutated to make them resistant to digestion by, for example, the proteases dipeptidyl peptidase IV (DPPIV), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), leukocyte elastase, cathepsin G, carboxypeptidase M, and carboxypeptidase N, but which retain chemoattractant activity. | 2011-09-15 |
| 20110224140 | HUMAN CHORIONIC GONADOTROPIN (HCG) ORALLY OR FOR INJECTION FOR THE TREATMENT OF MOOD DISORDERS AND ALCOHOLISM - An HCG preparation for oral administration or for injection used either as a simple dilution or coupled to albumin or a cyclodextrin therapeutically effective in the treatment of mood disorders including (but not limited to) neurosis, irritability, depressive states and borderline states. HCG preparation as above described is also effective in the treatment of all types of alcoholism. | 2011-09-15 |
| 20110224141 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER - A method of treatment and/or prevention of cancer comprises administering agents which cause increased intracellular granularity in cancer cells, at least in an amount sufficient to inhibit proliferation of such cells and preferably in an amount sufficient to lead to cancer cell death. The method is particularly directed to refractory cancer, particularly hormone refractory prostate cancer. The agents identified cause increased intracellular granularity in the cancer cells, and also convert adherent cancer cells to non-adherent cancer cells, leading to cancer cell death. Using the present invention, cancer cells undergo increased intracellular granularity at relatively low agent concentrations, while also inhibiting cell proliferation. Increased concentrations lead to conversion of adherent cancer cells to non-adherent cancer cells, then to cell death. While the exact mechanism of cancer cell degradation and death is not completely understood, the treated cancer cells, including refractory prostate cancer cells, give indications of cell death through an autophagic mechanism. Pharmaceutical compositions related to the presently disclosed methods are also disclosed. | 2011-09-15 |
| 20110224142 | PARATHYROID HORMONE RECEPTOR ACTIVATION AND STEM AND PROGENITOR CELL EXPANSION - The invention relates to methods for manipulating hematopoietic stem or progenitor cells, mesenchymal stem cells, epithelial stem cells, neural stem cells and related products through activation of the PTH/PTHrP receptor in neighboring cells. | 2011-09-15 |
| 20110224143 | NUCLEOBINDIN I VARIANT PROTEIN COMPOSITIONS AND METHODS OF USE - The invention relates to Nucleobindin-1 (NUCB1) protein variants that are capable of disaggregating amyloid fibrils as well as inhibiting the formation of fibrils in the presence of physiological concentrations of calcium. Isolated NUCB1 protein variants, nucleic acids encoding the protein variants, cells comprising the isolated nucleic acids, pharmaceutical compositions and kits comprising the variants, methods of making the variants, and therapeutic uses of the variants are provided. | 2011-09-15 |
| 20110224144 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MENTAL DISORDERS - The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia). The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders. | 2011-09-15 |
| 20110224145 | Neuromodulators and Methods of Use - The present disclosure provides neuromodulators, nucleic acid encoding thereof, and compositions thereof for endowing visual processing abilities to neuronal cells. The present disclosure further provides a method of restoring light sensitivity to degenerate retinas. | 2011-09-15 |
| 20110224146 | AUGMENTED COGNITIVE TRAINING - The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining cognitive training protocols and a general administration of CREB pathway-enhancing agents. | 2011-09-15 |
| 20110224147 | METHODS AND COMPOSITIONS - A method for inducing an analgesic response to inflammatory or neuropathic pain by administration of 1-(2-(4-chlorophenyl)-2-hydroxy)ethyl-4-(3,5-bis(1,1 dimethyl)-4-hydroxyphenyl)methyl piperazine, also called CNSB002 or AM-36, either alone or with an opioid and/or a neurokinin (NK) antagonist. | 2011-09-15 |
| 20110224148 | CARBOHYDRATE-POLYAMINO ACID-DRUG CONJUGATES - Compositions that include a polymer conjugate and glucosamine operatively associated with the polymer conjugate, wherein the polymer conjugate includes a first drug, are described herein. Also disclosed herein are methods of using such compositions to treat, ameliorate, or diagnose a disease or condition such as cancer. | 2011-09-15 |
| 20110224149 | POLYNUCLEOTIDES FOR USE IN TREATING AND DIAGNOSING CANCERS - The present invention provides methods for increasing sensitivity of cancer cells to an antiestrogen agent, such as a selective estrogen receptor modulator (SERM). The methods include administering to the subject a polynucleotide in an amount effective to increase the antiestrogen agent sensitivity of the cancer cells. The cancer cells may be estrogen receptor positive, such as ER-α66 positive or ER-α36 positive, prior to the administering. Also provided are methods for decreasing the amount of estrogen receptor present in a cancer cell, methods for determining whether antiestrogen agent sensitivity of cancer cells in a subject can be increased, methods for diagnosing whether a subject has, or is at risk for developing, cancer, and methods for identifying an agent that increases the amount of let-7 miRNA in a cell. | 2011-09-15 |
| 20110224150 | METHODS FOR EFFECTING REGRESSION OF TUMOR MASS AND SIZE IN A METASTASIZED TUMOR - The present invention relates generally to methods of effecting regression of tumor size and mass of a metastasized tumor in a subject by administering an effective amount of a desulphatohirudin variant. | 2011-09-15 |
| 20110224151 | Polymeric Micelle Composition for Treatment of Resistant Cancer and Preparation Method of the Same - Disclosed are a polymer micelle composition for treatment of resistant cancer cells that contains an amphiphilic double block copolymer and taxane and a P-glycoprotein inhibitor of cyclosporin as its active ingredients, and a method of preparing the same. Said polymer micelle composition for treatment of cancer resistant cells is accumulated in cancer tissue at high concentrations, and has the advantages that it exhibits superior anti-cancer effects for the cancer cells that have exhibited resistance due to over-expression of P-glycoprotein by the taxane anticancer agent in said cancer tissue, and does not cause hypersensitive reactions due to the use of a solubilizer. | 2011-09-15 |
| 20110224152 | SYNTHETIC ARGININE SUBSTITUTED PEPTIDES AND THEIR USE - The present invention relates to new arginine substituted peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and/or scars. | 2011-09-15 |
| 20110224153 | Asthma Associated Factors as Targets for Treating Atopic Allergies Including Asthma and Related Disorders - A C to T DNA variation at position 3365 in exon 5 of the human Asthma Associated Factor 1 (AAF1) produces the predicted amino acid substitution of a methionine for a threonine at codon 117 of AAF1. When this substitution occurs in both alleles in one individual, it is associated with less evidence of atopic allergy including asthma, fewer abnormal skin test responses, and a lower serum total IgE. Thus, applicant has identified the existence of a non-asthmatic, non-atopic phenotype characterized by methionine at codon 117 when it occurs in both AAF1 gene products in one individual. | 2011-09-15 |
| 20110224154 | PEPTIDE DERIVATIVE AND COMPOSITION FOR PROMOTING TEAR SECRETION COMPRISING THE SAME - A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition for promoting lacrimal secretion comprising a peptide derivative represented by the formula (I): | 2011-09-15 |
| 20110224155 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH - The present invention includes methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors, and modifiers capable of modulating chemosensory receptors and their ligands. The present invention also includes modifiers of chemosensory receptors and their ligands having Formula (I), its subgenus, and specific compounds. Furthermore, the present invention includes ingestible compositions comprising the modifiers of chemosensory receptors and their ligands and methods of using the modifiers of chemosensory receptors and their ligands to enhance the sweet taste of an ingestible composition or treat a condition associated with a chemosensory receptor. In addition, the present invention include processes for preparing the modifiers of chemosensory receptors and their ligands. | 2011-09-15 |
| 20110224156 | Propionic Acids, Propionic Acid Esters, and Related Compounds - The invention relates to propionic acids, propionic acid esters, and related compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds for the treatment of various diseases or conditions, including but not limited to diseases and/or conditions of Central Nervous System (CNS). | 2011-09-15 |
| 20110224157 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS - The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. | 2011-09-15 |
| 20110224158 | ESTERIFIED ALPHA-GALACTOSYLCERAMIDE - The invention provides esterified α-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): | 2011-09-15 |
| 20110224159 | BIDESMOSIDIC BETULIN AND BETULINIC ACID DERIVATIVES AND USES THEREOF AS ANTITUMOR AGENTS - The instant application is directed to bidesmosidic betulin and betulinic acid saponin derivatives of formula (I), and use thereof as antitumor agents. In particular, said compounds are effective in treating lung carcinomas, colorectal adenocarcinomas, breast adenocarcinomas, and prostate adenocarcinomas. Methods of synthesizing said compounds through selective glycosylation of the C-28 and C-3 position, and diagnostic methods for identifying tumours suitable for treatment by said compounds are also disclosed. | 2011-09-15 |
| 20110224160 | Use of Escin for Treatment of Type IV Hypersensitivity Reaction - The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment of a Type IV hypersensitivity reaction or symptoms of a Type IV hypersensitivity reaction, such as in contact dermatitis, atopic dermatitis, hypersensitivity pneumonitis, chronic transplant rejection, graft versus host disease, cell mediated autoimmune diseases, Hashimoto's thyroiditis, Sjogren's disease, adrenalitis, polymyositis, or pernicious anemia. | 2011-09-15 |
| 20110224161 | TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF - The present invention relates to tetracyclic anthraquinone antibiotic derivatives with anticancer activity. The tetracyclic anthraquinone antibiotic derivatives as provided in the present invention have the same or higher activity than that of the known drugs such as doxorubicin, daunorubicin and the like in the cellular level while having better tolerance than that of doxorubicin and daunorubicin in the animal body. | 2011-09-15 |
| 20110224162 | SYNTHETIC ANALOGUES OF PHOSPHATIDYL-MYO-INOSITOL MANNOSIDES WITH AN INHIBITORY ACTIVITY OF THE INFLAMMATORY RESPONSE - The present invention relates to novel synthetic analogues of phosphatidyl-myo-inositol mannosides (hereinafter referred to as PIMs) of general formula (I): or a pharmaceutically acceptable salt thereof, to the method for preparing same and to the use thereof in the prevention or treatment of a disease associated with the overexpression of cytokines or of chemokines, in particular of TNF and/or of IL-12. The invention also relates to a pharmaceutical composition comprising at least one synthetic derivative of PIM. | 2011-09-15 |
| 20110224163 | GEL COMPOSITION FOR EXTERNAL APPLICATION CONTAINING AN ADENINE COMPOUND (As Amended) - An object of the present invention is to provide a composition for external application that is applied to a part of the skin to more effectively elicit the useful effects of an adenine compound such as adenine, adenosine, and a phosphoric ester of adenosine, and that has long-lasting effects and enhanced skin-moisturizing effects. A gel composition for external application containing an adenine compound such as adenine, adenosine, and a phosphoric ester of adenosine is prepared by using agar as a gelling agent. The gel composition is further prepared in the form of a sheet-like adhesive patch. The gel composition in the form of a sheet-like adhesive patch is kept immersed in an aqueous solution containing the adenine compound. | 2011-09-15 |
| 20110224164 | FLUID COMPOSITIONS FOR IMPROVING SKIN CONDITIONS - The present specification discloses fluid compositions comprising a matrix polymer and stabilizing component, methods of making such fluid compositions, and methods of treating skin conditions in an individual using such fluid compositions. | 2011-09-15 |
| 20110224165 | FORMULATIONS AND METHODS FOR REDUCING WAIST CIRCUMFERENCE - Methods for reducing abdominal fat and waist circumference in a human subject are disclosed. The method includes a composition containing | 2011-09-15 |
| 20110224166 | COMPOSITION FOR ACTIVATING MITOCHONDRIA (As Amended) - The present invention relates to a composition for activating mitochondria which contains a chitooligosaccharide as an active constituent. The chitooligosaccharide can increase the activity of mitochondrial enzymes and increase the amount of mitochondrial DNA, and thus it can be suitably used as an active constituent in the composition for activating mitochondria. | 2011-09-15 |
| 20110224167 | Skin-Protecting Alkalinity-Controlling Composition and the Use Thereof - A skin-protecting alkalinity-controlling composition comprises one or more carboxylic acid polysaccharides. Said compositions are capable of providing buffering, and thus avoiding a major increase in the pH of an aqueous system and/or are capable of reducing the pH of aqueous systems, in which alkalinity is formed as a result of chemical and/or biological reactions. The compositions may be used in personal care products, such as skin creams and lotions, hygiene products, wound care products, fabric treating products etc. | 2011-09-15 |
| 20110224168 | FAT-BINDING COMPOSITIONS - A fat-binding composition contains an inclusion complex with a host molecule and a guest molecule. The guest molecule includes one or more amino acids, vitamins, flavorants or related compounds, rutin, betanin, derivatives thereof, and mixtures thereof. The fat-binding composition may be in the form of a tablet or powder, for example, and may be incorporated into a food or beverage product. If in the form of a powder or tablet, the composition may optionally contain a carbonation-forming component and may be dissolved in carbonated or non-carbonated water. The fat-binding composition may also be employed in a method for binding fat ingested by an animal which includes having the animal ingest the composition, or a food or beverage product containing the same. | 2011-09-15 |
| 20110224169 | HYALURONIC ACID OLIGOSACCHARIDE FRACTIONS AND DRUGS CONTAINING THE SAME - A method for promoting expression of a heat shock protein, or for inhibiting cell injury or cell death, or for treating a disease for which cell or tissue protection is desired, or for promoting production of IL-10, or for inhibiting production of IL-8, by administering an effective amount of a fraction containing a hyaluronic acid tetrasaccharide comprising four saccharide residues and having certain physicochemical properties or by administering an effective amount of an isolated and substantially pure tetrasaccharide of formula (1) described in the application. Methods for preserving an organ. | 2011-09-15 |
| 20110224170 | Pyranopyranone derivatives as antimicrobial agents - Disclosed is the use of pyranopyranone derivatives of formula | 2011-09-15 |
| 20110224171 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE - The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). | 2011-09-15 |
| 20110224172 | Substituted 1-Oxa-2,8-Diaza-Spiro [4,5] Dec-2-Ene Derivatives and Related Treatment Methods - Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene compounds and processes for their production, the use thereof for producing pharmaceutical compositions, pharmaceutical compositions containing these compounds and methods of treatment using these compounds. | 2011-09-15 |
| 20110224173 | C2-C5-Alkyl-Imidazole-Bisphosphonates | 2011-09-15 |
| 20110224174 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS - The present invention provides a creatine ester anti-inflammatory compound which may be received by animals and then metabolized into a biologically active form of creatine. The biologically active creatine inhibits the production of chemical mediators, released during an inflammatory response, which are important components in the inflammatory response and the inflammation and pain resulting from physical or chemical trauma to cells and tissue. | 2011-09-15 |
| 20110224175 | FORMULATIONS OF CANFOSFAMIDE AND THEIR PREPARATION - Formulations of canfosfamide and their preparation. | 2011-09-15 |
| 20110224176 | Lyophilized Cake Formulations - Provided herein are lyophilized cake forms of fluticasone, salmeterol, or a pharmaceutically acceptable salt or a combination thereof which provides room temperature stability for an extended period of time. Upon reconstitution with an acceptable solvent (e.g., a carrier or diluent), the reconstituted pharmaceutical or cosmetic formulation provides a sterile, non-suspension form suitable for parenteral injectable administration, including subcutaneous injection. | 2011-09-15 |
| 20110224177 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS - A combination which comprises (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid. | 2011-09-15 |
| 20110224178 | Composition and method for treating erectile dysfunction - Erectile dysfunction in a male human patient is ameliorated by oral administration to the patient of a phosphodiesterase type 5 (PDE5) inhibitor, such as sildenafil, and a glucocorticoid such as prednisone. | 2011-09-15 |
| 20110224179 | MEDICAMENT AND METHOD OF DIAGNOSIS - We disclose a diagnostic test to determine suitable therapeutic intervention of subjects suffering from subclinical Cushing's syndrome [SCS] and also agents that antagonise the action of cortisol or inhibit excess cortisol production in the treatment of conditions such as SCS in the presence of an adrenal incidentaloma. | 2011-09-15 |
| 20110224180 | NOVEL CHOLEST-4-EN-3-ONE OXIME DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND PREPARATION METHOD - The present invention relates to novel chemical compounds, in particular cholest-4-en-3-one oxime derivatives and to the use thereof as medicaments, especially as cytoprotective medicaments, in particular neuroprotective, cardioprotective and/or hepatoprotective medicaments. | 2011-09-15 |
| 20110224181 | METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY - Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject. | 2011-09-15 |
| 20110224182 | SALTS OF (3-0-(3',3'-DIMETHYLSUCCINYL) BETULINIC ACID AND SOLID STATE FORMS THEREOF - The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, methods of making the compounds, polymorphic forms of the compounds, the compounds for use as medicaments, and use of the compounds for the manufacture of medicaments. The present invention also concerns a method of treatment involving administration of the compounds. Specifically, the compounds are certain salts of 3-O-(3′,3′-dimethylsuccinyl)betulinic acid, also known as “DSB.” The novel compounds are useful as antiretroviral agents. In particular, the novel compounds are useful for the treatment of Human Immunodeficiency Virus (“HIV”). | 2011-09-15 |
| 20110224183 | 16, 17-CARBOCYCLIC CONDENSED STEROID COMPOUNDS HAVING SLECTIVE ESTROGENIC ACTIVITY - The invention discloses a steroid compound having the formula (1): | 2011-09-15 |
| 20110224184 | NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS - The present invention provides pharmaceutical compositions comprising substituted 1,4 naphthoquinones that are effective in preventing oligomerization of beta amyloid and subsequent pathologies associated with amyloid fibrils. These compositions are useful for the treatment of disease involving amyloidogenesis including neurodegenerative diseases such as Alzheimer's Disease or senile dementia. Particularly effective compositions comprise 1,4 naphthoquinones substituted with an amino acid residue selected from a heterocyclic or aromatic amino acid. | 2011-09-15 |
| 20110224185 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119. | 2011-09-15 |
| 20110224186 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS - Carbacephem β-lactam antibiotics having the following chemical structure (I) are disclosed: | 2011-09-15 |
| 20110224187 | PYRROLIDINE, PIPERIDINE AND PIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF - The present invention relates to novel Pyrrolidine, Piperidine and Piperazine Derivatives, pharmaceutical compositions comprising the Pyrrolidine, Piperidine and Piperazine Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity, an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. | 2011-09-15 |
| 20110224188 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES - Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease. | 2011-09-15 |
| 20110224189 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES - The present invention provides compounds of the formula: | 2011-09-15 |
| 20110224190 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS - The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases. | 2011-09-15 |
| 20110224191 | Substituted Pyrrolo[2,3-b]-Pyridines and -Pyrazines - Compounds of Formula I, as shown below and defined herein: (I) pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by Ron and/or Met. | 2011-09-15 |
| 20110224192 | 3-Arylamino Pyridine Derivatives - The invention provides novel, substituted 3-arylamino pyridine compounds | 2011-09-15 |
| 20110224193 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE - The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the invention is shown with this abstract. | 2011-09-15 |
| 20110224194 | Staurosporine Derivatives as Inhibitors of FLT3 Receptor Tyrosine Kinase Activity - The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity. | 2011-09-15 |
| 20110224195 | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES - The present invention is directed to substituted six-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as obesity and diabetes, particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 2011-09-15 |
| 20110224196 | TREATMENT OF OBSTRUCTIVE SLEEP APNEA SYNDROME WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ADDITIONAL ACTIVE AGENT - This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil, eszopiclone, zolpidem, zaleplon, and phentermine. | 2011-09-15 |
| 20110224197 | PYRIMIDINES AND PYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinases, such as inhibitors of GSK-3. The invention provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. The invention provides processes for preparing compounds of the invention. The invention provides methods of identifying compounds useful for treatment of diabetes, diabetic neuropathy, osteoporosis, Alzheimer's disease, Huntington's disease, Parkinson's disease, AIDS-associated dementia, bipolar disorder, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, leukocytopenia, cardiomyocyte hypertrophy, stroke, post-stroke, spinal cord injury, traumatic brain injury, Charcot-Marie-Tooth, peripheral nerve regeneration, and rheumatoid arthritis. | 2011-09-15 |
| 20110224198 | ARYL METHYL BENZOQUINAZOLININE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention is directed to benzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 2011-09-15 |
| 20110224199 | Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues - Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I | 2011-09-15 |
| 20110224200 | THERAPEUTIC AGENT FOR CHORIORETINAL DEGENERATIVE DISEASE CONTAINING PYRIDINE-3-CARBALDEHYDE 0-(PIPERIDIN-1-YL-PROPYL)-OXIME DERIVATIVE AS ACTIVE INGREDIENT - Provided is a novel prophylactic or therapeutic agent for a chorioretinal degenerative disease. The compound of formula (1) or its salt has inhibitory effects on photoreceptor cell death or visual cell death in a mouse model of light damage. Therefore, the compound or its salt is useful as a prophylactic or therapeutic agent for a chorioretinal degenerative disease such as age-related macular degeneration, retinitis pigmentosa. In the formula (1), A is a group (p1), (p2) or (p3); R | 2011-09-15 |
| 20110224201 | CGRP RECEPTOR ANTAGONISTS - Compounds of Formula (I), (wherein variables A | 2011-09-15 |
| 20110224202 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS - Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. Pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs of the compounds are also provided. Also disclosed are compositions containing a compound in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same. | 2011-09-15 |
| 20110224203 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS - The invention provides compounds of the formula (I): | 2011-09-15 |
| 20110224204 | DI-SUBSTITUTED PHENYL COMPOUNDS - Di-substituted phenyl compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. The disclosure also relates to methods for treating neurological, neurodegenerative and psychiatric disorders including but not limited to those comprising cognitive deficits or schizophrenic symptoms. | 2011-09-15 |
| 20110224205 | USE OF CURCUMIN OR ITS ANALOGUES IN CANCER THERAPY UTILIZING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR - Provided is combined use of an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and curcumin or its analogue in cancer therapy, which reduces side effects resulting from the EGFR-TKI and reduces doses of the EGFR-TKI needed for the therapy, particular in a patient resistant to the treatment with the EGFR-TKI alone. | 2011-09-15 |
